Study #2019-0390
Immune Related Toxicity and Symptom Burden In Chronic Cancer Survivors With Melanoma Receiving Adjuvant Immunotherapy With Immune Checkpoint Inhibitors
MD Anderson Study Status
Enrolling
Treatment Agent
Description
This study evaluates the immune related toxicity and symptom burden in chronic cancer survivors with melanoma who are receiving adjuvant immunotherapy with immune checkpoint inhibitors. Information collected in this study may help doctors to learn more about the side effects caused by immunotherapy, and to learn if there are any relationships between these side effects and immune and genetic biomarkers found in the blood that may be related to patient's reaction to immunotherapy.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Clinical Stage III Cutaneous Melanoma AJCC v8;Pathologic Stage III Cutaneous Melanoma AJCC v8;Pathologic Stage IIIA Cutaneous Melanoma AJCC v8;Pathologic Stage IIIB Cutaneous Melanoma AJCC v8;Pathologic Stage IIIC Cutaneous Melanoma AJCC v8;Pathologic Stage IIID Cutaneous Melanoma AJCC v8;Melanoma, Stage II;Melanoma Stage IV
Study phase:
Physician name:
Noha Hassan
Department:
Melanoma Medical Oncology
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.